| Similar Articles |
|---|
 |
The Motley Fool
October 26, 2010
Selena Maranjian |
Make Money in Biotech the Simple Way These ETFs present an easy way to invest in biotechnology.   |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
The Motley Fool
September 20, 2005
Brian Gorman |
Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note. |
The Motley Fool
September 23, 2008
Brian Lawler |
Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released. |
The Motley Fool
March 3, 2009
Brian Orelli |
Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think. |
The Motley Fool
July 14, 2008
Brian Orelli |
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone. |
The Motley Fool
August 12, 2008
Charly Travers |
The Mark of Winning Stocks Never underestimate the importance of a moat. |
The Motley Fool
November 6, 2006
Brian Lawler |
The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note. |
The Motley Fool
September 11, 2007
Brian Lawler |
Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note. |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
The Motley Fool
July 16, 2009
Brian Orelli |
A Strong Dollar Can Hurt Novartis makes it through a hard quarter. |
The Motley Fool
May 15, 2008
Brian Orelli |
Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch. |
The Motley Fool
October 26, 2011
Selena Maranjian |
Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you. |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
May 5, 2009
Robert Steyer |
Sanofi-Aventis' To-Do List The French drugmaker seeks acquisitions to reinforce and expand its business geographically and scientifically. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
December 1, 2008
Zoe Van Schyndel |
A Better Way to Invest in Biotech? Structured as a trust, the Biotech HOLDR holds common stock of companies in the biotechnology industry. But don't confuse HOLDRs with exchange-traded funds. |
Managed Care
April 2007
Martin Sipkof |
Abbreviated Approval Process In the Works for 'Biosimilar' Drugs The Access to Life-Saving Medicine Act may be a first step to giving the FDA the legal authority to approve these drugs. |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different? |
The Motley Fool
June 25, 2007
Brian Orelli |
Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
June 15, 2011
Selena Maranjian |
Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF. |
The Motley Fool
February 14, 2008
Brian Lawler |
Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops. |
The Motley Fool
June 11, 2009
Brian Orelli |
The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics. |
The Motley Fool
August 18, 2008
Zoe Van Schyndel |
Funds for a Sick Economy? The biotech sector has been a sleeper with positive returns. Take a look at two biotech mutual funds that are performance leaders. |
National Real Estate Investor
May 1, 2006
F. R. Skinner |
Bulking Up On Biotech Investing in the development of a highly unique, medical-grade building is only going to appeal to a select niche of investors. But with biotech returns averaging some 1% to 2% higher than the general office market, it is a smart play for investors wanting a diversified portfolio. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
January 31, 2007
Zoe Van Schyndel |
Health Care, Thinly Sliced Five new health-care-focused ETFs, the HealthShares family, provide increasingly specific ways to invest in health care. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
April 9, 2010
Brian Orelli |
Double Your Biotech Returns! Really! Taking a closer look at leveraged biotech ETFs. |
BusinessWeek
April 4, 2005
Arlene Weintraub |
Biotech's Fountain Of Youth A review of the book "More Than Human: Embracing the Promise of Biological Enhancement." The book by Ramez Naam provides a look at biotech's role in the future of medicine. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
November 8, 2007
Charly Travers |
BioMarin Tips Its Hand BioMarin Pharmaceutical awaits an FDA decision on its drug Kuvan for the treatment of phenylketonuria. The company's recent conference call implies approval is imminent. |
The Motley Fool
May 5, 2005
Brian Gorman |
Boning Up at Genzyme In its latest acquisition, the biotech claims a line of products from Bone Care. But is the company spreading itself a little too thin? |
The Motley Fool
July 30, 2004
Roger Nusbaum |
Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability. |
The Motley Fool
June 22, 2007
Brian Lawler |
Novartis' Good Week The pharma receives a pair of positive regulatory decisions. Investors, take note. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
The Motley Fool
August 30, 2010
Brian Orelli |
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition? |
Chemistry World
April 24, 2008
James Mitchell Crow |
FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches. |
Pharmaceutical Executive
July 30, 2007
Jill Wechsler |
Washington Report: Exclusivity vs. Patents To encourage innovation while supporting access to less costly therapies, Congress proposes an extensive data-exclusivity period that would delay Food and Drug Administration approval of a follow-on biologic application for 12 years. |
The Motley Fool
October 31, 2007
Brian Lawler |
Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note. |
Chemistry World
July 15, 2009
Matt Wilkinson |
Exxon and Venter to create fuel of the future Oil giant ExxonMobil has finally entered the biofuel race and signed up biotechnology company Synthetic Genomics (SGI) to help produce next generation biofuels from photosynthetic algae. |
Chemistry World
February 17, 2011
Sarah Houlton |
Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share. |
The Motley Fool
June 1, 2005
Rich Duprey |
Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then. |
The Motley Fool
November 16, 2006
Jim Fink |
The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007. |
The Motley Fool
April 12, 2006
Selena Maranjian |
Are ETFs Getting out of Control? Prepare to be dazzled by exchange-traded funds for every kind of commodity. What should investors do about this proliferation? |
The Motley Fool
February 10, 2009
Robert Steyer |
Rx for a Drug Deal? Will circumstance and psychology prod Sanofi-Aventis into a big acquisition? |
